Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

Figure 3

Mean (± SD) serum pateclizumabpharmacokinetic profiles (A) and CXCL13 profiles (B) by cohort. CXCL13 is presented as the percentage change from baseline. Arrows indicate pateclizumabdoses. BL = baseline; CXCL13 = chemokine (C-X-C motif) ligand 13; IV = intravenously; LTα = lymphotoxin α; MAD = multiple ascending dose; SAD = single ascending dose; SC = subcutaneously.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us